Curriculum Vitae Alexander J. Lepak, M.D.

Transcription

1 Curriculum Vitae Alexander J. Lepak, M.D. Personal Data Office Infectious Disease UW Medical Foundation Centennial Building, Room Highland Ave Madison, WI Phone Fax Laboratories Microbial Sciences Building Room Linden Drive Madison, WI Phone William S. Middleton Memorial Veterans Hospital Room D Overlook Terrace Madison, WI Phone ext Education & Training Undergraduate: Bachelor of Science, University of Wisconsin-Madison Medical School: University of Wisconsin-Madison NIH-GCRC Mentored Medical Student Research Program Mentor: David Andes Residency Training: University of Wisconsin Hospital and Clinics, Madison WI, Internal Medicine Clinical Fellowship: University of Wisconsin Hospital and Clinics, Madison WI, Infectious Disease Research Fellowship: NRSA T32 Ruth L. Kirschstein National Research Service Award, PI: Bruce Klein, Mentors: David Andes and William Craig Board Certification and Licensure 2008-present Internal Medicine 2010-present Infectious Diseases 2007-present State of Wisconsin License to Practice Medicine and Surgery Current Appointment 2013-present Assistant Professor of Medicine Department of Medicine Division of Infectious Disease University of Wisconsin School of Medicine and Public Health Past Positions and Appointments

2 1998 Research Assistant, University of Wisconsin, Department of Veterinary Medicine, PI: Dr. Benjamin Darien, DVM 2000 Associate Research Specialist, University of Wisconsin, Department of Pharmacology, PI: Bernard Weisblum, MD Postdoctoral trainee, University of Wisconsin, Department of Medical Microbiology and Immunology Clinical Instructor & Research Associate, University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Infectious Disease Professional Societies 2008-present Infectious Diseases Society of America 2003-present American Society for Microbiology Honors/Awards Dean s Lists 1999 Phi Kappa Phi 1999 Graduated with Distinction, College of Letters & Science, University of Wisconsin-Madison 2002 NIH-GCRC Mentored Medical Student Clinical Research Grant Award ICAAC Infectious Disease Fellows Grant Program Recipient Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training (T32) Grant Award 2010 George McCracken Infectious Disease Fellow, American Society for Microbiology National Institutes of Health, Division of Loan Repayment Program for Clinical Research Award Recipient, University of Wisconsin School of Medicine and Public Health, Madison, WI Research Support/Grants Current: [1] Antimicrobial Drug Discovery from Coevolved Symbiotic Communities Sponsor: NIH/NIAID 1 U19 AI Role: Collaborator PI: David Andes, Cameron Currie 2014-current Major Past Awards: [1] NIH/GCRC: Mentored Medical Student Clinical NIH GCRC M01 RR03186 Sponsor: NIH-GCRC [2] Investigator-Initiated Studies Program: Identification of the pharmacodynamic target for caspofungin and posaconazole used alone and in combination against drug susceptible and drug resistant Aspergillus fumigatus strains in a murine model of Invasive Pulmonary Aspergillosis (IPA). Sponsor: Merck Role: Collaborator PI: David Andes

3 [3] Ruth L. Kirschstein National Research Service Award (NRSA) Training Grant Sponsor: NIH 5 T32 AI PI: Bruce Klein [4] National Institutes of Health Loan Repayment Program Sponsor: NIH Publications Abbreviation Key: CDD = concept development and design MEN = mentoring DAQ = data acquisition ALS = analysis WRT = writing Underlined name reflects trainee Peer reviewed publications: 1. Andes D, Lepak A, Pitula A, Marchillo K, Clark J. A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site. J Infect Dis 2005;192(5): PMID: Policy exempt Accepted for pub prior to 04/07/08. CDD 50%, MEN 0%, DAQ 90%, ALS 70%, WRT 40% 2. Lepak A, Nett J, Lincoln L, Marchillo K, Andes D. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob Agents Chemother 2006;50(4): PMID: PMCID: PMC CDD 50%, MEN 0%, DAQ 90%, ALS 90%, WRT 60% 3. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 2006;50(7): PMID: PMCID: PMC CDD 25%, MEN 0%, DAQ 25%, ALS 40%, WRT 30% 4. Andes D, Lepak A, Nett J, Marchillo K, Lincoln L. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob Agents Chemother 2006;50(7): PMID: PMCID: PMC CDD 40%, MEN 0%, DAQ 25%, ALS 50%, WRT 40% 5. Lepak A, Andes D. Pharmacodynamics of Antifungal Drugs: A Strategy to Optimize Efficacy. Current Fungal Infection Reports 2008;2(1): Policy exempt Accepted for pub prior to 04/07/08. CDD 90%, MEN 0%, DAQ N/A, ALS N/A, WRT 95% 6. Nett JE, Lepak AJ, Marchillo K, Andes DR. Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis 2009;200(2): PMID: PMC CDD 30%, MEN 0%, DAQ 50%, ALS 50%, WRT 25% 3

4 7. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo Comparison of the Pharmacodynamic Target Among Echinocandin Drugs and Candida species. Antimicrob Agents Chemother 2010;54(6): PMID: PMCID: PMC CDD 30%, MEN 0%, DAQ 0%, ALS 30%, WRT 25% 8. Lepak A, Andes D. Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. Crit Care Clin 2011;27(1): PMID: Policy exempt Review. CDD 95%, MEN 0%, DAQ N/A, ALS N/A, WRT 95% 9. Lepak A, Andes D. Antifungal PK/PD Considerations in Pulmonary Fungal Infections. Semin Respir Crit Care Med 2011;32(6): PMID: Policy exempt Review. CDD 95%, MEN 0%, DAQ N/A, ALS N/A, WRT 95% 10. Andes D, Lepak A. Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting it Right the First Time. Clin Infect Dis 2012;55(3): PMID: Policy exempt Not resulting from NIH funding. CDD 50%, MEN 0%, DAQ N/A, ALS N/A, WRT 50% 11. Lepak AJ, Castanheira M, Diekema D, Pfaller M, Andes DR. Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via in vivo pharmacodynamic evaluation Against C. glabrata with and without Fks Mutations. Antimicrob Agents Chemother 2012;56(11): PMID: PMCID: PMC CDD 80%, MEN 0%, DAQ 90%, ALS 95%, WRT 90% 12. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. Comparative Pharmacodynamics of a new Oxazolidinone Tedizolid and Linezolid in a Neutropenic Murine Staphylococcus aureus Pneumonia Model. Antimicrob Agents Chemother 2012;56(11): PMID: PMCID: PMC CDD 40%, MEN 0%, DAQ 10%, ALS 100%, WRT 95% 13. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Posaconazole Pharmacodynamic Target Determination against Wild-type and Cyp51 Mutant isolates of Aspergillus fumigatus in an in vivo model of Pulmonary Aspergillosis. Antimicrob Agents Chemother 2013;57(1): PMID: PMCID: PMC CDD 95%, MEN 0%, DAQ 95%, ALS 100%, WRT 95% 14. Lepak AJ, Marchillo K, VanHecker J, Forrest A, Andes DR. Impact of in vivo Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against Cyp51 Mutant Isolates. Antimicrob Agents Chemother 2013;57(11): PMID: PMCID: PMC CDD 95%, MEN 0%, DAQ 95%, ALS 100%, WRT 95% 15. Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM. Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. Antimicrob Agents Chemother 2013;57(11): PMID: PMCID: PMC CDD 30%, MEN 0%, DAQ 0%, ALS 30%, WRT 40% 16. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole Pharmacodynamic Target Determination for Candida species in an in vivo Murine Disseminated Invasive Candidiasis Model. Antimicrob Agents Chemother 4

5 2013;57(11): PMID: PMCID: PMC CDD 90%, MEN 0%, DAQ 95%, ALS 100%, WRT 95% 17. Lepak AJ, Marchillo K, VanHecker J, Andes DR. Isavuconazole (BAL 4815) Pharmacodynamic Target Determination in an in vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild Type and Cyp51 Mutant Isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2013;57(12): PMID: PMCID: PMC CDD 90%, MEN 0%, DAQ 95%, ALS 100%, WRT 95% 18. James S. Lewis II, Lepak AJ, Thompson GR 3 rd, Craig WA, Andes DR, Sabol-Dzintars KE, Jorgensen JH. Failure of Clindamycin to Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections. Antimicrob Agents Chemother 2014;58(3): PMID: PMCID: PMC CDD 25%, MEN 0%, DAQ 30%, ALS 40%, WRT 20% 19. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2014;58(10): PMID: PMCID: PMC CDD 50%, MEN 100%, DAQ 95%, ALS 100%, WRT 70% 20. Lepak AJ, Marchillo K, Craig WA, Andes DR. In vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic, NAI-107, in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother 2015;59(2): PMID: PMCID: PMC CDD 40%, MEN 0%, DAQ 50%, ALS 100%, WRT 90% 21. Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), using an In Vivo Murine Invasive Candidiasis Model. Antimicrob Agents Chemother 2015;59(2): PMID: PMCID: PMC CDD 50%, MEN 0%, DAQ 50%, ALS 100%, WRT 80% 22. Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR. In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. Antimicrob Agents Chemother 2015;59(10): PMID: PMCID: PMC CDD 50%, MEN 100%, DAQ 50%, ALS 100%, WRT 95% 23. Lepak A, Marchillo K, VanHecker J, Andes D. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target. Antimicrob Agents Chemother 2015;epub ahead of print Sep 21. PMID: PMCID: pending. CDD 50%, Men 0%, DAQ 25%, ALS 100%, WRT 75% Book Chapters: 1. Andes D, Lepak AJ. Antifungal Pharmacodynamics. In: Kauffman CA, Pappas PG, Sobel JD, and Dismukes WE (Eds) Essentials of Clinical Mycology, 2nd Edition Springer Press. 2. Lepak AJ and Andes DR. Antifungal Pharmacokinetics and Pharmacodyanmics. In: Casadevall A, Mitchell AP, Berman J, Kwon-Chung KJ, Perfect JR, Heitman J (Eds) Human Fungal Pathogens Cold Spring Harbor Laboratory Press 5

6 3. Lepak A, Andes D. Antifungal Pharmacodynamics. In: Vesga O, Leiderman E, Restrepo A, and Velez LA (Eds) Enfermedades infecciosas de Homo sapiens. (Translated: Infectious Disease of Homo Sapiens), 1st edition Corporacion para Investigaciones Biologicas 4. Andes DR, Lepak AJ, Frimodt-Moller N. Evaluation of Antimicrobials in Experimental Animal Infections. In: Amsterdam D (Ed) Antibiotics in Laboratory Medicine, 6th Edition Wolters Kluwer 5. Andes DR, Lepak AJ. Animal Models of Invasive Fungal Infections, 2015, Submitted Abstracts: 1. D. Andes, A. Lepak, A. Pitula, J. Smith. In Vitro Fluconazole Pharmacodynamic Impact on the Transcription of Genes Associated with C. albicans Drug Resistance. 43 rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, D. Andes, A. Lepak. Relationship Between Fluconazole Pharmacodynamic Exposure In Vitro and S. cerevisiae Genome Expression. 43 rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, D. Andes, A. Lepak, K. Marchillo, A. Pitula. Impact of fluconazole postantifungal effect on mrna abundance of CDR1 and CDR2 efflux pumps in a murine infection model. 44 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, D. Andes, A. Lepak, K. Marchillo, J. Nett, A.Pitula, J. Smith. Fluconazole pharmacodynamics and the emergence of Candida albicans resistance in an in vivo infection model. 44 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, A. Lepak, Andes D. Candida albicans Global Transcriptional Profile During and Following Fluconazole Exposure Gene Expression PAE. 45 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, L. Lincoln, J. Nett, A. Lepak, M. Van Handel, D. Andes. Analysis of the global transcriptional profile of C. albicans cells from an in vivo catheter biofilm model. Candida and Candidiasis, American Society for Microbiology, D. Andes, A. Lepak, D. Diekema, M. Pfaller, K. Marchillo, J. Bohrmuller. Identification of the In Vivo Pharmacodynamic (PD) Target for Echinocandins against C. albicans (CA), C. glabrata (CG), and C. parapsilosis (CG) in the Neutropenic Murine Disseminated Candidiasis Model. Abstract A th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, A. Lepak, H. Sanchez, K. Marchillo, D. R. Andes. Comparative Pharmacodynamics (PD) of a Triazole and Echinocandin for Invasive Pulmonary Aspergillosis (IPA). Abstract A th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Boston, MA,

7 9. N. W. Moore, A. J. Lepak, T. D. Moon. Infectious Complications Following Transrectal Prostate Biopsy at a Single Institution. 84 th Annual Meeting of the North Central Section of the American Urological Association, Selected for presentation at the national meeting, the 107 th Annual Meeting of the American Urological Association, M. C. Arendrup, A. Lepak, W. Hope, D. R. Andes. Comparison of the in vivo Pharmacodynamics (PD) of An Echinocandin and Triazole Based Upon Use of Clsi and Eucast Susceptibility Methods. Abstract A st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, IL, A. Lepak, A. Forrest, K. Marchillo, D. R. Andes. Dose Ranging Pharmacodynamics (PD) of Echinocandin (E) and Triazole (T) Combination Antifungal Therapy in an In Vivo Pulmonary Aspergillosis (IPA) Model. Abstract A st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, IL, A. Lepak, K. Marchillo, D. R. Andes. In Vivo Pharmacodynamics (PD) Characterization of the Novel Lantabiotic, Nai-107 in the Neutropenic Murine Thigh Model Against S. aureus. Abstract F st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, IL, D. R. Andes, A. Lepak, K. Marchillo. In-vivo Pharmacodynamic (PD) Target for the Oral Glucan Synthase Inhibitor (GSI), MK-3118 (MK) Against C. albicans (CA), C. glabrata (CG), and C. parapsilosis (CP) in the Neutropenic Murine Disseminated Candidiasis Model. Abstract A st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, IL, A. Lepak, K. Marchillo, W. Craig, D. R. Andes. In vivo Evaluation of a Novel Carbapenemase Inhibitor (CPI), Rpx7009, in Combination with the Carbapenem Rpx2003 against 2 KPC Producing K. pneumoniae (KP) in a Neutropenic Murine Thigh Model. Abstract F nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, C. C. Bulik, O. O. Okusanya, S. M. Bhavnani, A. Lepak, P. G. Ambrose, J.L. Hoover, D. R. Andes. Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of GSK (GSK052) against Gram-Negative Bacilli (GNB) in a Murine-Thigh Infection Model. Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, D. R. Andes, O. O. Okusanya, C. C. Bulik, A. Lepak, S. M. Bhavnani, A. Forrest, J. L. Hoover, P. G. Ambrose. Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of GSK (GSK052) against Gram-Negative Bacilli (GNB) Using Data from a Neutropenic Murine-Pneumonia Infection Model. Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. J. Lepak, W. A. Craig, D. R. Andes, K. Marchillo, J. van Hecker. Reduced Activity of Clindamycin against Various Streptococci with Clindamycin-Inducible Resistance in the Neutropenic Thigh Infection Model. Abstract D nd Interscience Conference on 7

8 Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, M. Castanheira, M. Pfaller, D. Diekema, D. R. Andes. Pharmacodynamic (PD) Evaluation of 3 Echinocandins (E) against C. glabrata (CG) with and without Fks Mutations in the Neutropenic Disseminated Candidiasis Model. Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, D. R. Andes, A. Forrest. In Vivo Pharmacodynamic (PD) Evaluation of Combination Triazole (T) and Echinocandin (E) Therapy against Susceptible and Resistant A. fumigatus (AF). Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, K. Marchillo, J. Cabezas, D. R. Andes. Isavuconazole (ISA) Pharmacodynamic (PD) Target Determination C. albicans (CA) in an In Vivo Neutropenic Murine Model of Invasive Candidiasis (IC). Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, K. Marchillo, J. VanHecker, D. R. Andes. Pharmacodynamics (PD) of Posaconazole (P) in a Murine Invasive Pulmonary Aspergillosis (IPA) model against Wild Type and Cyp51 Mutant isolates. Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, K. Marchillo, J. Cabezas, W. Craig, D. R. Andes. In Vivo Pharmacodynamic (PD) Characterization of a New Fluoroquinolone (FQ) Antibiotic, Kpi-10, against Gram- Positive (GP) and Gram-Negative (GN) bacteria. Abstract A nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA, A. Lepak, K. Marchillo, J. vanhecker, D. Andes. Pharmacodynamics (PD) of Isavuconazole (Isav) in a Murine Invasive Pulmonary Aspergillosis (IPA) Model Against Wild type (WT) and Cyp51 Mutants. Abstract A-291. Selected for oral presentation at the 53 rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Denver, CO, A. Lepak, K. Marchillo, J. vanhecker, D. Diekema, D. Andes. Impact of Candida species on the Isavuconazole (ISA) Pharmacodynamic (PD) Target in an in vivo Neutropenic Murine Model of Invasive Candidiasis (IC). Abstract A rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Denver, CO, D. Andes, D. K. Reynolds, S. A. Van Wart, A. Lepak, L. L. Kovanda, S. M. Bhavnani. Clinical Pharmacodynamic (PD) Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. Abstract A rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Denver, CO,

9 26. S.L. Burke, D.R. Andes, P.T. Trapskin, B.C. Fox, A.J. Lepak, S. Rough, L.T. Schulz. Creation of an Antimicrobial Stewardship Outreach Program. University Healthsystem Consortium Annual Pharmacy Meeting, Orlando, FL, S.L. Burke, D.R. Andes, P.T. Trapskin, B.C. Fox, A.J. Lepak, S. Rough, L.T. Schulz. Creation of an Antimicrobial Stewardship Outreach Program. Podium Presentation, Great Lakes Pharmacy Resident Conference. West Lafayette, IN, A. Lepak, A. Reda, K. Marchillo, J. VanHecker, D. Andes. In vivo Pharmacodynamic Target Evaluation of Ceftolozane against Streptococcus and Pseudomonas in a Neutropenic Murine Thigh Infection Model. 24 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, C. C. Bulik, O. O. Okusanya, S. M. Bhavnani, A. Lepak, A. Forrest, P. G. Ambrose, J. L. Hoover, D. R. Andes. Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of GSK ('944) against Staphylococcus aureus (SA) and Streptococcus pneumoniae (SP) in a murine thigh-infection model. 54 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington D.C., S. Free, M. Daeda, J. Smith, K. Reed, B. Fox, A. Lepak, L. Schulz. Evaluating Procalcitonin in Guiding Antimicrobial Therapy for Lower Respiratory Tract Infections: A Retrospective Analysis. University of Wisconsin Health Quality Week. Madison, WI M. Brennan, A. Lepak. Low Procalcitonin Results Seldom Trigger Antibiotic Deescalation in Hospitalized Patients. University of Wisconsin Department of Medicine Research Day. Madison, WI, A. Lepak, P. Seiler, J. P. Surivet, D. Ritz, C. Kohl, D. R. Andes. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a novel Topoisomerase inhibitor ACT in a murine thigh and lung infection model against Staphylococcus aureus (SA) and Streptococcus pneumoniae (SPN). 55 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA, A. Lepak, P. Seiler, J. P. Surivet, D. Ritz, C. Kohl, D. R. Andes. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a novel Topoisomerase inhibitor ACT in a murine thigh and lung infection model against Staphylococcus aureus (SA) and Streptococcus pneumoniae (SPN). 55 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA, A. Lepak and D. R. Andes. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Antibiotic compound TXA-709 and its active metabolite TXA-707 (TXA-709/707) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model. 55 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA, A. Lepak, N. Azie, D. R. Andes. Efficacy of Micafungin Extended Interval Dosing (EID) for Prophylaxis (PPX) and Treatment (TX) of Invasive Candidiasis (IC) in a Murine 9

10 Model. 55 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA, A. Lepak and D. R. Andes. Pharmacodynamic (PD) Activity of Dalbavancin against VISA Staphylococcus aureus (SA) Isolates in the Neutropenic Murine Thigh Infection Model. ID Week, Infectious Diseases Society of America, San Diego, CA, M. B. Brennan, K. Osterby, L. Schulz, A. J. Lepak. Disconrdant Effectiveness of Low versus High Procalcitonin (PCT) Results on Antibiotic Administration in Hospitalized Patients. ID Week, Infectious Diseases Society of America, San Diego, CA, 2015 Invited Research Presentations Local: 2007 Antifungal Prophylaxis in Hematological Malignancy. Department of Medicine Advances in Medicine Seminar Madison WI 2008 Antifungal Pharmacodynamics, Optimizing Therapy. Department of Medicine Advances in Medicine Seminar Madison WI 2011 Old Dog New Tricks: Use of Pharmacodynamic Approaches to Optimize Aspergillus Therapy. Microbes in Health and Disease Seminar Madison WI 2012 Invasive Fungal Infections and Drug Resistance: In vivo Pharmacodynamic Models to Optimize Therapy. Microbes in Health and Disease Seminar Madison WI National/International: 2013 Pharmacodynamics (PD) of Isavuconazole (Isav) in a Murine Invasive Pulmonary Aspergillosis (IPA) Model Against Wild type (WT) and Cyp51 Mutants. 53 rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Denver CO 2014 Old and New Anti-infective Agents from a Pharmacokinetic-Pharmacodynamic Perspective Isavuconazole. 54 th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington D.C. Patents none Educational Activities & Presentations Classroom Teaching: Year Location Title Audience 2009 University of Wisconsin Hospital and Clinics Internal Medicine Resident Seminar University of Wisconsin Physician Assistant Program Invited Seminar Antibiotic review: Bug-Drug and difficult to treat microorganisms Antibiotic Review for the Physician Assistant in Training Internal Medicine Residents, Medical Students PA Students 10

11 2010 University of Wisconsin Physician Assistant Program Invited Seminar 2011 University of Wisconsin School of Medicine and Public Health, 2 nd Year Medical School Foundations in Medicine Course 2012 University of Wisconsin Infectious Disease Fellowship Curriculum Internal Medicine Resident Lecture series: Guidance and Implementation of UWHC Infectious Disease Guidelines and Antimicrobial Stewardship initiatives (Recurring Monthly) University of Wisconsin Infectious Disease Fellowship Curriculum University of Wisconsin Infectious Disease Fellowship Curriculum 2015 Dept of Veterans Affairs, Madison WI, Podiatric Medicine and Surgery Residency Lecture Series/Journal Club Antibiotic Review and Management Pearls for Commonly Encountered Outpatient Infectious Diseases Enteric Viral Infections Small Group Leader Malaria Guidelines: Procalcitonin, Beta-lactam Allergy, SSTI, HCAP, CAP, and UTI Malaria Aspergillus Basic Principles of Antimicrobial Pharmacokinetics and Pharmacodynamics (PK/PD) PA Students Medical Students Fellows, Internal Medicine Residents, Medical Students Internal Medicine Residents Fellows, Internal Medicine Residents, Medical Students Fellows, Internal Medicine Residents, Medical Students Podiatry Staff and Residents CME Presentations: Year Location Title Audience 2013 University of Wisconsin 2013 Dennis G. Maki Infectious Disease Update Cases from the Clinic: Antibiotic Resistance in Outpatients Physicians, Physician Assistants, Nurse Practitioners and other 2014 University of Wisconsin 35 th Annual Madison Clinical Conference: The Pharmacists Role in Management of Infectious Diseases th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington D.C. Azole Therapeutic Drug Monitoring Old and New Anti-infective Agents from a Pharmacokinetic- Pharmacodynamic Perspective Isavuconazole health care providers State and Regional Pharmacy practitioners National and International Infectious Disease providers and pharmacists 2015 University of Wisconsin - Hot Antibiotic Resistance: Physicians, Physician 11

12 Topics in Internal Medicine 2015: The Latest Knowledge to Impact Your Practice Approach to Challenging Cases in Ambulatory Care Assistants, Nurse Practitioners and other health care providers Mentoring: [1] Undergraduate: Anne Reda Anne is an undergraduate student with career goals as a future Pharm D who approached our lab to obtain experience and training in pharmacodynamic studies. I have mentored her in numerous research principles including approach, design, data acquisition, analysis, and writing of PD studies. She has acquired numerous laboratory and analysis skills under my mentoring. She has successfully participated on a number of projects and has presented her work for class credit. [2] Post-Graduate: Stuart Burke Stuart is a Pharm D resident in Infectious Disease through the UW School of Pharmacy residency program. I have mentored Stuart on a number of stewardship-related projects. His stewardship research projects have been presented at both local and regional pharmacy meetings. [3] Undergraduate: Michaela Madison Michaela joined our PK/PD research lab as an undergraduate student majoring in Medical Microbiology and Immunology. She wanted to gain research experience in applied microbiology techniques looking at treatment efficacy studies and PK/PD design and analysis. She is completing a PK/PD study and analysis currently. [4] Post-Graduate: Ronald Kendall Ron is a Pharm D resident in Infectious Disease through the UW School of Pharmacy residency program. I have mentored him on a number of stewardship-related projects. These projects have resulted in successful implementation of a number of hospital guidelines. Service/Committees Years Service/Role UWHC Infection Control Committee VAH Infection Control Committee UW Infectious Disease Fellowship Education Committee 2008-present UWHC Antimicrobial Use Subcommittee, Pharmacy and Therapeutics Committee 2010-present UWHC Inpatient Infectious Disease Consultant 2010-present UWHC Outpatient Infectious Disease Clinic 2010-present Meriter Hospital Infectious Disease Consultant 2010-present William S. Middleton Memorial Veterans Hospital Inpatient Infectious Disease Consultant 2010-present UW Internal Medicine Residency applicant interviewer 2010-present UW Infectious Disease Fellowship applicant interviewer 2012-present UWHC Antimicrobial Stewardship Physician 2012-present UW Infectious Disease Fellowship Clinical Competency Committee 2012-present UW Infectious Disease Fellowship Program Evaluation Committee 2013-present UWHC Infectious Disease Pharmacy Resident Education & Research Mentor 12

13 Journal Review Antimicrobial Agents and Chemotherapy Journal of Antimicrobial Chemotherapy Diagnostic Microbiology and Infectious Disease Clinical Microbiology Reviews 13